Solid Biosciences (SLDB) Common Equity (2017 - 2024)
Historic Common Equity for Solid Biosciences (SLDB) over the last 8 years, with Q3 2024 value amounting to $167.0 million.
- Solid Biosciences' Common Equity rose 1569.75% to $167.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $167.0 million, marking a year-over-year increase of 1569.75%. This contributed to the annual value of $126.5 million for FY2023, which is 4024.5% down from last year.
- Latest data reveals that Solid Biosciences reported Common Equity of $167.0 million as of Q3 2024, which was up 1569.75% from $193.2 million recorded in Q2 2024.
- In the past 5 years, Solid Biosciences' Common Equity ranged from a high of $253.0 million in Q1 2021 and a low of $22.2 million during Q3 2020
- Its 5-year average for Common Equity is $161.4 million, with a median of $167.0 million in 2024.
- As far as peak fluctuations go, Solid Biosciences' Common Equity plummeted by 7951.53% in 2020, and later surged by 90473.66% in 2021.
- Over the past 5 years, Solid Biosciences' Common Equity (Quarter) stood at $132.1 million in 2020, then skyrocketed by 57.63% to $208.2 million in 2021, then grew by 1.66% to $211.7 million in 2022, then plummeted by 40.25% to $126.5 million in 2023, then soared by 32.05% to $167.0 million in 2024.
- Its Common Equity stands at $167.0 million for Q3 2024, versus $193.2 million for Q2 2024 and $210.7 million for Q1 2024.